Climb­ing the block­buster moun­tain, Roche/Ab­b­Vie team her­alds a win in front­line CLL PhI­II

Ab­b­Vie $AB­BV and Roche have post­ed a goal on their piv­otal com­bi­na­tion of Ven­clex­ta and Gazy­va for front­line cas­es of chron­ic lym­pho­cyt­ic leukemia, which should help boost their block­buster dreams for added rev­enue.

We don’t have the hard da­ta yet, but the com­pa­nies are al­ready hus­tling their com­bo da­ta to reg­u­la­tors in hopes of ex­pand­ing the mar­ket for Ven­clex­ta.

In this study their com­bo beat out Gazy­va plus chlo­ram­bu­cil in pro­duc­ing a sol­id ad­van­tage for pro­gres­sion-free sur­vival. That should give the com­pa­ny’s boost­ers en­cour­age­ment in be­liev­ing this drug can push past the $2 bil­lion a year mark to­ward $3 bil­lion in peak sales — which would make this drug a big con­trib­u­tor to both of their bot­tom lines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER